文献速递创伤骨科骨质疏松与代谢性骨病

区域协调电子健康支持的骨折联络服务:股骨脆性骨折后试点随机对照试验

A territorially coordinated, eHealth-supported fracture liaison service following femur fragility fracture: a pilot randomised controlled trial.
PubMed 文献 · Osteoporos Int · 2026-09-28

该试点随机对照试验在≥65岁手术治疗的股骨脆性骨折成人中比较电子健康支持的骨折联络服务(FLS)与常规护理,共纳入119例(FLS组60例,常规护理组59例)。结果显示FLS组功能恢复更好且骨质疏松治疗处方更持续,但再骨折和再入院无显著差异。

要点

  • 电子健康支持的FLS在股骨脆性骨折后第一年可改善功能恢复。
  • FLS组骨质疏松治疗处方比常规护理更持续。
  • 再骨折和再入院两组无显著差异,需更大样本验证。

核心结论

  • 区域协调电子健康支持的FLS可行,且与常规护理相比在股骨脆性骨折后第一年功能恢复更好、骨质疏松治疗处方更持续。
  • 再骨折和再入院无显著差异,支持在更大研究中进一步评估数字化协调的区域FLS模式。

研究设计与样本

  • 多中心试点项目包括两个阶段:先评估基于网络平台的技术性能和可用性,随后进行前瞻性开放标签实效研究。
  • 随机纳入119例≥65岁且手术治疗的股骨脆性骨折成人,分为电子健康支持的FLS路径组(n=60)和常规护理组(n=59)。

主要发现

  • FLS组在整个随访期间功能恢复更高,3、6和12个月Barthel指数显著更高(12个月时80.1 vs. 61.2;P ≤ 0.01)。
  • 再入院两组相似,再骨折不常见且无显著差异。
  • FLS组骨质疏松治疗处方更持续。
  • 全部8例死亡均发生在FLS组,对照组无死亡;鉴于样本量小,不应解读为因果效应。

关键数值与推荐

  • 12个月Barthel指数:FLS组80.1 vs. 常规护理组61.2(P ≤ 0.01)。
  • 主要结局为再骨折和再入院;次要结局包括功能恢复、纵向骨质疏松治疗处方、治疗依从性、死亡率和数字平台的专业可用性。

临床怎么用

  • 对于手术治疗的股骨脆性骨折成人,可考虑采用区域协调电子健康支持的FLS路径以改善功能恢复和骨质疏松治疗持续性。
  • 再骨折和再入院方面未显示显著获益,临床决策需结合更大样本证据。

局限性

  • 试点研究样本量小(共119例),死亡等事件解读需谨慎。
  • FLS组基线骨折前功能状况更有利,可能影响功能恢复比较。
  • 开放标签设计可能存在偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: A territorially coordinated, eHealth-supported Fracture Liaison Service (FLS) was implemented to standardize secondary fracture prevention across an Integrated Health Area. Following a pilot usability study, a 1-year randomized trial compared the eHealth-supported FLS with usual care in adults aged ≥ years with surgically treated femur fragility fractures. Primary outcomes included refractures and hospital readmissions, while secondary outcomes assessed functional recovery, longitudinal osteoporosis treatment prescription, treatment adherence, mortality, and professional usability of the digital platform. PURPOSE: Fracture Liaison Services (FLS) improve secondary fracture prevention, but implementation remains heterogeneous and digital integration is limited. We evaluated the feasibility and clinical impact of a territorially coordinated, eHealth-supported FLS standardising post-fracture care across an Integrated Health Area. METHODS: This multicentre pilot project comprised two phases: an initial study evaluating a web-based platform's technical performance and usability, followed by a prospective, open-label effectiveness study randomising 119 adults aged ≥65 years with surgically treated femur fragility fractures to an eHealth-supported FLS pathway (n = 60) or usual care (n = 59). Primary outcomes were refractures and hospital readmissions; secondary outcomes included functional recovery, treatment prescription, mortality and platform usability. RESULTS: Baseline characteristics were comparable, although the FLS group had a more favourable pre-fracture functional profile. Functional recovery was higher in the FLS group throughout follow-up, with significantly higher Barthel Index scores at 3, 6 and 12 months (80.1 vs. 61.2 at 12 months; P ≤ 0.01). Readmissions were similar and refractures infrequent, without significant differences. Osteoporosis treatment prescription was more sustained in the FLS group. All eight deaths occurred in the FLS group and none in control; given the small sample, this should not be read as a causal effect. CONCLUSIONS: A territorially coordinated, eHealth-supported FLS was feasible and was associated with better functional recovery and more sustained osteoporosis treatment prescription than usual care in the first year after femur fragility fracture. No significant differences were observed in refractures or readmissions; findings support further evaluation of digitally coordinated territorial FLS models in larger studies. TRIAL REGISTRATION: ClinicalTrials.gov NCT05266755, registered prospectively on 23 February 2022.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Martín Marcuello J, Rodolico A, Britez Carli ML, et al. A territorially coordinated, eHealth-supported fracture liaison service following femur fragility fracture: a pilot randomised controlled trial. Osteoporos Int. 2026. PMID: 42803811. doi:10.1007/s00198-026-08219-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。